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O

NGOING DEBATES IN THE PHARMACEUTICAL

sector about intellectual property,1,2 pricing
and reimbursement,3,4 and public research
investments5 have a common denominator: the pursuit of innovation. However, there is little clarity about
what constitutes a true pharmaceutical innovation,
and as a result there is confusion about what kind of
new products should be pursued, protected and encouraged through health policy and clinical practice.6
If the concept of pharmaceutical innovation can be
clarified, then it may become easier for health policymakers and practitioners to evaluate, adopt and procure products in ways that appropriately recognize,
encourage and give priority to truly valuable pharmaceutical innovations.
To describe a product as innovative implies that it
has properties that are worthy of recognition and reward. The term suggests that the product has unique

value. However, notions of value are a matter of perspective. Commercial value, for example, is generally
assessed from the perspective of a firm’s profitability.
The perceived societal value of ordinary goods is often
defined by consumer preferences as reflected by their
willingness to pay for products that they perceive to be
“good value for money.” However, pharmaceuticals
are not ordinary goods.
Pharmaceutical products have no intrinsic value to
patients or to society; rather, their value lies in the
health outcomes they generate. Pharmaceuticals are
licensed for sale on the basis of whether they safely
and efficaciously address a health care need, not because patients might have preferences concerning
their shape, colour, taste or brand. Although characteristics like shape, colour, taste or brand may play a
role in improving health outcomes — perhaps by increasing treatment adherence — it is the measurable
improvements in health outcomes that generate
value for society. Product characteristics are analogous to surrogate endpoints in clinical trials insofar
as they are of societal value only to the extent that
they predict clinical or “hard” endpoints.7,8
Although the concepts of novelty and innovation
are often associated with one another,9 defining the
societal value of pharmaceuticals exclusively in terms
of the production of health outcomes implies that
product novelty alone does not constitute pharmaceutical innovation. New chemical structures or
mechanisms of action do not necessarily generate
improved health outcomes:10,11 a new pharmaceutical
product must also have some degree of effectiveness
(net of treatment risks). 6 It should be noted that effectiveness alone is not enough to qualify a new
product as an innovation. A generic drug, for example, may safely and efficaciously address a health
care need — and may provide value to patients and
society — but it would hardly be considered an innovation. Thus, neither novelty nor effectiveness alone
is enough to qualify as pharmaceutical innovation.
Even the combination of novelty and effectiveness is
not enough.
Pharmaceutical innovation requires novelty of effectiveness. Pharmaceutical innovations create value to
society by making it possible to generate improvements
in patient health (net of treatment risks) that were previously unattainable. It is the uniqueness of such health
improvements that defines pharmaceutical innova-
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tions. A drug can be considered a pharmaceutical innovation only if it meets otherwise unmet or inadequately
met health care needs. This will depend on its efficacy,
safety and convenience of use relative to the technologies available when it is introduced. For example,
cimetidine, the prototypical histamine-2 receptor antagonist, was considered a pharmaceutical innovation
when it was introduced in 1977 because it safely and effectively addressed a previously inadequately met
need.12 However, the notion of pharmaceutical innovation is time-dependent. Competition and technological
change mean that the standard by which the unique
value of a pharmaceutical innovation is measured —
the ability to address health care needs that are otherwise not addressable — will change over time. Neither
cimetidine nor other histamine-2 receptor antagonists
would be considered innovations today because the
outcomes they generate have been matched and even
surpassed by other technologies.
Replicating outcomes obtainable with existing
treatments is important for market competition but
it does not represent innovation. However, surpassing existing levels of performance in terms of
established efficacy, safety or both would be considered pharmaceutical innovation. Again, consider
advances in gastroenterology: the first proton pump
inhibitor, omeprazole, was an innovation when it was
introduced in 1989 because it met a given need more
effectively than histamine-2 receptor antagonists.
Proton pump inhibitors have since become the mainstay of treatment for acid-related gastrointestinal
disease in adults. Although they continue to generate
valuable outcomes, they would no longer be considered innovations.
A pharmaceutical innovation may be thought of as
incremental, substantial or radical according to the
significance of the unmet health care need it addresses (gravity of unmet need) and the extent to
which it improves net health outcomes related to that
need (comparative effectiveness) (Figure 1). The
gravity of an unmet need can be thought of as the gap
between the health status that patients with a particular medical condition could attain with existing
technologies and the health status they could expect
if they did not have that medical condition. The lowest gravity of unmet need (a value of zero) represents
cases in which patients experience no deprivation in
health status if they receive existing treatments or

cases in which the nature of the condition is trivial in
terms of health status (e.g., male pattern baldness).
The highest gravity of unmet need (a value of 1) represents cases in which the condition has a prognosis
of immediate death given existing treatment options.
Gravity of unmet need establishes the potential
for pharmaceutical innovation (i.e., the maximum
improvement in health status that a new drug might
offer, over and above existing technologies). For a
condition with a low gravity of unmet need, such as
colour blindness, there is a limited potential for
pharmaceutical innovation. To determine the level
of pharmaceutical innovation that a drug actually
achieves, one must also examine its comparative effectiveness in terms of net improvements in health
outcomes, taking into account the negative effects of
the drug (e.g., side effects and adverse events).
Drugs with zero comparative effectiveness offer no
improvement in health outcomes compared with existing treatments. The highest possible comparative
effectiveness (a value of 1) indicates the ideal (and
seldom, if ever, realized) situation in which a drug is
perfectly safe and entirely closes the gap between
the health status attainable with prevailing treatments and the ideal health status for the treated
population. The categories of innovation in Figure 1
are drawn with a lower border because a medicine
must offer some level of comparative health benefit
to be considered an innovation, no matter how
grave the condition it aims to remedy.
The greater the gravity of the unmet need addressed by a new treatment, or the greater its
comparative effectiveness in addressing that need,
the greater the degree of pharmaceutical innovation.
Radical innovations, or “breakthroughs,” are moderately to highly effective treatments for conditions
that would otherwise significantly reduce the quality
or length of life or both, or treatments that provide a
near-total cure in cases in which the prevailing unmet needs are more moderate. Substantial
innovations offer fair to modest improvements in
health outcomes for patients with grave unmet
needs, or substantial improvements over existing
treatments for patients whose unmet health care
needs are less serious. Finally, incremental innovations offer minor to moderate improvements over
existing treatments for patients whose unmet needs
are moderate to trivial.
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Figure 1: A model of pharmacological innovation

Breakthrough drugs (or radical pharmaceutical
innovations) generate the most significant societal
value through their unique ability to generate improvements in health outcomes not otherwise
possible. To qualify as a breakthrough, a new drug
must offer significant improvements over existing
treatments, even when the prevailing unmet needs
are dire. For example, a drug that briefly extends
the life expectancy of terminally ill patients might
be considered an innovation, but to be considered a
breakthrough it would have to provide these patients with a quantity and quality of life close to
what they could have expected in the absence of the
underlying illness. For this reason, the breakthrough category does not intersect with the lower
horizontal line of Figure 1.
There is limited scope for pharmaceutical innovation for conditions for which existing therapies offer
relatively good outcomes. New treatments within a
drug class may offer modest therapeutic gains in efficacy or safety, but being different does not in itself
constitute innovation. For example, early and late
entrants into a drug class might each be more effective or better tolerated among certain population
subgroups. However, late entrants will not represent significant pharmaceutical innovation unless
they are systematically superior to early ones.
The value of new drugs that produce outcomes
similar to those achievable with other treatment options lies not in innovation but in the potential

competition that these products may bring to the
marketplace. Such competition may have value for
consumers and for society more generally through
reduced costs per outcome achieved. However, the
cost of developing such medicines includes the significant investment and the risks to participants in
various stages of clinical trials, as well as the funds
spent on marketing efforts to differentiate the new
drug from existing treatments, and all of these costs
divert resources from the pursuit of treatments to
meet more substantial unmet health needs. 1,13,14
Ultimately, it is commercial value that drives investments and activities in the private sector. Firms
may strive for commercial performance by developing drugs that effectively address grave, unmet health
care needs. Firms may also be commercially innovative without generating pharmaceutical innovations,
such as when they develop a marketing campaign
that builds brand loyalty for a product that is comparable to existing alternatives. Indeed, when Figure 1
is viewed from a societal perspective on a global or
national basis, it appears that most of the commercial activity in the pharmaceutical market is focused
on product development and related marketing activities in therapeutic areas in which new products
would at best provide incremental advances in population health. That is, much of the innovation in this
sector is commercial, not pharmaceutical.
The fact that commercial incentives are not always aligned with the production of major
pharmaceutical innovations is evident not only in
the global divide between burden of illness and drug
research and development, 15,16 but also in the share
of product development, marketing and sales in
wealthy countries that is accounted for by medicines
that offer little or no advantage over established
treatment alternatives. 17 Between 1993 and 2004,
only one-third of US applications for the licensing
of new molecular entities were promising enough to
qualify for priority review by the US Food and
Drugs Administration. 18 The proportion of new
drugs that represent true breakthroughs is likely
lower. Between 1981 and 2000, Prescrire International rated only 74 (3%) of nearly 2300 new drugs
or new indications for existing drugs as major or
important therapeutic gains. 19 Fewer than 10% of
recently developed biotechnology drugs and cancer
treatments have been deemed to offer substantial
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improvements with respect to hard clinical endpoints. 20,21
Ultimately, the pharmaceutical industry is not to
blame. The industry’s focus on research and marketing activities for products that do not
dramatically advance attainable health outcomes
results from the way drugs are appraised, selected
and purchased by health practitioners, patients,
policy-makers and insurers. If these actors placed a
premium on true pharmaceutical innovation—
demonstrably safe and effective treatments for previously unmet needs—and encouraged competition
among technologies that produce equivalent health
outcomes, private investments in research and development would be stimulated in the areas of
greatest value to society. 4
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